SCHEMBL5314368

SCHEMBL5314368

N#Cc1cccc(OCCCBr)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TBXAS1 P24557 1/20 0.52
▸ GSK3B P49841 1/20 0.46
▸ HRH1 P35367 1/20 0.44
▸ CCR3 P51677 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP11B1 P15538 1/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ KCNA3 P22001 1/20 0.41
▸ F2 P00734 1/20 0.41
▸ PLG P00747 1/20 0.41
▸ PRSS1 P07477 1/20 0.41
▸ PRSS2 P07478 1/20 0.41
▸ C1S P09871 1/20 0.41
▸ PRSS3 P35030 1/20 0.41
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4948901 0.95 TBXAS1 (0.51) TBXAS1GSK3BHRH1CCR3KCNA3
SCHEMBL11033727 0.93 TBXAS1 (0.50) TBXAS1GSK3BPRSS1
SCHEMBL22120309 0.93 TBXAS1 (0.50) TBXAS1GSK3BPRSS1
SCHEMBL30826996 0.93 TBXAS1 (0.50) TBXAS1GSK3BPRSS1
SCHEMBL3901418 0.91 TBXAS1 (0.54) TBXAS1GSK3BHRH1CCR3SMN1; SMN2
SCHEMBL7388461 0.87 TBXAS1 (0.56) TBXAS1HRH1CCR3KCNA3PRSS1
SCHEMBL688706 0.84 TBXAS1 (0.54) TBXAS1HRH1CCR3SMN1; SMN2CYP11B1
SCHEMBL27969567 0.84 TBXAS1 (0.49) TBXAS1GSK3BSMN1; SMN2SLC6A2SLC6A4
SCHEMBL10051067 0.83 TBXAS1 (0.52) TBXAS1HRH1CCR3SMN1; SMN2CYP11B1
SCHEMBL689001 0.83 TBXAS1 (0.52) TBXAS1GSK3BHRH1CCR3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101619-B2 Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition SOLVAY PHARMACEUTICALS B.V. (NL) 2012-01-24 — — US disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 — — US disclosed
WO-2007069986-A1 NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2007-06-21 — — WO disclosed
US-6534535-B1 Administering indole derivative as anticoagulant MILLENNIUM PHARMACEUTICALS, INC. 2003-03-18 — — US disclosed
EP-1183235-A2 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2002-03-06 — — EP disclosed
WO-2000071510-A2 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2000-11-30 — — WO disclosed
US-6130217-A ANTITUMOR PFIZER INC (US) 2000-10-10 — — US disclosed
US-5510375-A VIRICIDES TREATING INFECTION CAUSED BY HUMAN IMMUNODEFICIENCY VIRUS AND AIDS WARNER-LAMBERT COMPANY (US) 1996-04-23 — — US disclosed
WO-1994022846-A1 COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS PFIZER INC. (US) 1994-10-13 — — WO disclosed
Send feedback